Transferrin modified ruthenium nanoparticles with good biocompatibility for photothermal tumor therapy.

In the past two decades, there were various kinds of photothermal agents being synthesised and investigated for their photothermal effect in antitumor applications. However, it is barely reported that the photothermal effect of Ruthenium (Ru) nanoparticles was researched in depth. In this work, we introduced Ru nanoparticles which possess excellent biocompatibility and metabolize easily to the photothermal therapy field. In addition, to improve the cells capacity of absorbing Ru nanoparticles, these Ru nanoparticles were modified by transferrin (Tf-RuNPs). Subsequently, as is expected, the RuNPs exhibit a remarkably integrated and high-quality photothermal property. On the other hand, it is significantly that Tf modification could also strengthen the cells absorptive ability to uptake Ru nanoparticles through endocytosis., Furthermore, both the in vitro cell ablation and in vivo tumor treatment verified that the Tf-RuNPs became ideal photothermal agents for photothermal tumor ablation therapy owing to their low toxicity and high cell destruction capability.